Back to Journals » Biologics: Targets and Therapy » Volume 9

Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib

Authors Bardy-Bouxin N, Matczak E, Devgan G, Woloj M, Shapiro M

Received 18 December 2014

Accepted for publication 9 January 2015

Published 19 February 2015 Volume 2015:9 Pages 23—24

DOI https://doi.org/10.2147/BTT.S79507


Nathalie Bardy-Bouxin, Ewa Matczak, Geeta Devgan, Mabel Woloj, Mark Shapiro

Pfizer Oncology, Pfizer Inc., New York, NY, USA

Miller et al1 recently reviewed the role of ponatinib in chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), yet by the omission of an approved agent within the same class of drugs, provided an inaccurate summary of the current treatment landscape for CML.

View original paper by Miller and colleagues.


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]